Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EPS (Basic) (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EPS (Basic) for 11 consecutive years, with -$0.04 as the latest value for Q1 2025.

  • On a quarterly basis, EPS (Basic) rose 76.47% to -$0.04 in Q1 2025 year-over-year; TTM through Mar 2025 was -$0.52, a 10.34% increase, with the full-year FY2024 number at -$0.59, down 1.72% from a year prior.
  • EPS (Basic) was -$0.04 for Q1 2025 at Crescent Biopharma, up from -$0.16 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.04 in Q1 2025 to a low of -$0.34 in Q3 2021.
  • A 5-year average of -$0.2 and a median of -$0.17 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 55.56% in 2021, then surged 76.47% in 2025.
  • Crescent Biopharma's EPS (Basic) stood at -$0.33 in 2021, then soared by 42.42% to -$0.19 in 2022, then rose by 26.32% to -$0.14 in 2023, then dropped by 14.29% to -$0.16 in 2024, then soared by 75.0% to -$0.04 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's EPS (Basic) are -$0.04 (Q1 2025), -$0.16 (Q3 2024), and -$0.15 (Q2 2024).